Anti-EPCAM/CD3 bispecific mRNA-LNP
EpCAM (epithelial cell adhesion molecule, or CD326) is a transmembrane glycoprotein that mediates Ca2+-independent homotypic cell-cell adhesion in epithelial cells. EpCAM is overexpressed in many cancers and is also expressed in cancer stem cells, making EpCAM an attractive target for immunotherapy. EpCAM is expressed on the basolateral membrane of all epithelial cells, except normal squamous stratified epithelium that is EpCAM negative. EpCAM is cleaved into an extracellular domain (EpEX) and an intracellular domain (EpICD). EpICD forms a complex with other proteins in the nucleus and promotes the transcription of various genes, including the oncogene c-myc. This has been linked to promoting tumor growth. EpEX can stimulate the cleavage of additional EpCAM molecules, creating a positive feedback loop. CD3 (cluster of differentiation 3) is a protein complex that serves as a surface marker found on all T lymphocytes. Anti-EpCAM/CD3 bispecific antibodies provide a tool to identify EpCAM as a therapeutic target. This product is designed as a tool for the delivery and expression of anti-EPCAM/CD3 bsAb mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-EPCAM/CD3 bsAb mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The full-length amino acid sequence of this anti-EPCAM/CD3 bsAb mRNA-LNP product is available upon request.